Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) - Pipeline Review, H1 2018

Publisher Name :
Date: 12-Jun-2018
No. of pages: 35
This report is available at 20% Discount for Single User License till 03 August 2018. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.

Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) - Pipeline Review, H1 2018

Summary

Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) pipeline Target constitutes close to 6 molecules. Out of which approximately 3 molecules are developed by companies and remaining by the universities/institutes. The latest report Metabotropic Glutamate Receptor 1 - Pipeline Review, H1 2018, outlays comprehensive information on the Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) - Metabotropic glutamate receptor 1 (mGluR1) is a protein encoded by GRM1. It activates a phosphatidylinositol-calcium second messenger system. It participates in the central action of glutamate in the CNS, such as long-term potentiation in the hippocampus and long-term depression in the cerebellum. The molecules developed by companies in Phase III, Phase I and Preclinical stages are 1, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively. Report covers products from therapy areas Central Nervous System and Oncology which include indications Attention Deficit Hyperactivity Disorder (ADHD), Depression, Generalized Anxiety Disorder (GAD), Infantile Spasm (West Syndrome), Melanoma, Pervasive Developmental Disorder (PDD), Schizophrenia and Status Epilepticus.

Furthermore, this report also reviews key players involved in Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1)

- The report reviews Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) targeted therapeutics and enlists all their major and minor projects

- The report assesses Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

This report is available at 20% Discount for Single User License till 03 August 2018. To avail discount please contact at +1-888-391-5441 / sales@rnrmarketresearch.com.

Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) - Pipeline Review, H1 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) - Overview
Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) - Companies Involved in Therapeutics Development
Aevi Genomic Medicine Inc
Biohaven Pharmaceutical Holding Company Ltd
Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) - Drug Profiles
fasoracetam - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FC-311 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JBPOS-0101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize mGlu1 for Schizophrenia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize mGluR1 for Depression - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VU-0467558 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) - Dormant Products
Metabotropic Glutamate Receptor 1 (GPRC1A or MGLUR1 or GRM1) - Product Development Milestones
Featured News & Press Releases
May 10, 2017: Aevi Genomic Medicine Announces Plans to Initiate Phase 2 Clinical Trial to Confirm Genetic Responders to AEVI-001
Apr 20, 2017: Aevi Genomic Medicine Presents Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD
Apr 12, 2017: Aevi Genomic Medicine to Present Updated Results from SAGA Trial of AEVI-001 at the 6th World Congress on ADHD
Mar 20, 2017: Aevi Genomic Medicine Provides Top-line Results from the SAGA Trial of AEVI-001
Jan 31, 2017: Aevi Genomic Medicine Announces Enrollment of First Patient in Phase 1/2 Clinical Trial of AEVI-001 in 22q Deletion Syndrome
Jan 04, 2017: Aevi Genomic Medicine Announces Completion of Enrollment for Phase 2/3 SAGA Clinical Trial of AEVI-001 (NFC-1) in mGluR+ ADHD Adolescents
Oct 29, 2016: Medgenics Presents New Data Showing Prevalence of Genetic Mutations in Pediatric Populations with Attention Deficit Hyperactivity Disorder
Jun 17, 2016: Medgenics Announces Enrollment of First Patient in Phase 2/3 Clinical Trial of NFC-1 in Adolescents With mGluR Mutation Positive ADHD
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Aevi Genomic Medicine Inc, H1 2018
Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H1 2018
Dormant Projects, H1 2018

List of Figures
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
  • Global Plasminogen Market by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 20-Jul-2018        Price: US 3480 Onwards        Pages: 132
    Plasminogen, the proenzyme of the fibrinolytically active enzyme plasmin, is a single chain glycoprotein with a molecular weight of about 90,000-94,000 Da (2). Various isoelectric forms exist and can be separated by means of isoelectric focusing (IEF). The complete amino acid sequence contains 790 amino acids. Native plasminogen (glu-plasminogen) has a N-terminal glutamic acid group. Partial plasma proteolysis gives rise to a molecule with N-terminal lysine (lysplasminogen). ......
  • Global (North America, Europe, Asia-Pacific, South America, Middle East and Africa) Plasminogen Market 2018, Forecast to 2023
    Published: 20-Jul-2018        Price: US 4880 Onwards        Pages: 132
    Plasminogen, the proenzyme of the fibrinolytically active enzyme plasmin, is a single chain glycoprotein with a molecular weight of about 90,000-94,000 Da (2). Various isoelectric forms exist and can be separated by means of isoelectric focusing (IEF). The complete amino acid sequence contains 790 amino acids. Native plasminogen (glu-plasminogen) has a N-terminal glutamic acid group. Partial plasma proteolysis gives rise to a molecule with N-terminal lysine (lysplasminogen). ......
  • Global Chronic Inflammatory Demyelinating Polyneuropathy Drug Market Professional Survey Report 2018
    Published: 19-Jul-2018        Price: US 3500 Onwards        Pages: 108
    This report studies the global Chronic Inflammatory Demyelinating Polyneuropathy Drug market status and forecast, categorizes the global Chronic Inflammatory Demyelinating Polyneuropathy Drug market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, India, Southeast Asia and other regions (Central & South America, and Middle East & Africa). The global Chronic Inflammatory Demye......
  • Global Cluster Headache Syndrome Drug Market Professional Survey Report 2018
    Published: 19-Jul-2018        Price: US 3500 Onwards        Pages: 118
    This report studies the global Cluster Headache Syndrome Drug market status and forecast, categorizes the global Cluster Headache Syndrome Drug market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, India, Southeast Asia and other regions (Central & South America, and Middle East & Africa). The global Cluster Headache Syndrome Drug market is valued at million US$ in 2017 and......
  • Global Hodgkin Lymphoma Treatment Market Professional Survey Report 2018
    Published: 19-Jul-2018        Price: US 3500 Onwards        Pages: 118
    This report studies the global Hodgkin Lymphoma Treatment market status and forecast, categorizes the global Hodgkin Lymphoma Treatment market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, India, Southeast Asia and other regions (Central & South America, and Middle East & Africa). The global Hodgkin Lymphoma Treatment market is valued at million US$ in 2017 and will reach ......
  • Global Medical Morphine Market Professional Survey Report 2018
    Published: 19-Jul-2018        Price: US 3500 Onwards        Pages: 108
    This report studies the global Medical Morphine market status and forecast, categorizes the global Medical Morphine market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, India, Southeast Asia and other regions (Central & South America, and Middle East & Africa). Morphine is a pain medication of the opiate variety which is found naturally in a number of plants and animals. I......
  • Global MMR Vaccines Market Professional Survey Report 2018
    Published: 19-Jul-2018        Price: US 3500 Onwards        Pages: 108
    This report studies the global MMR Vaccines market status and forecast, categorizes the global MMR Vaccines market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, India, Southeast Asia and other regions (Central & South America, and Middle East & Africa). The MMR vaccine (also known as the MPR vaccine after the Latin names of the diseases) is an immunization vaccine against ......
  • Global Herpes Zoste Drug Market Professional Survey Report 2018
    Published: 19-Jul-2018        Price: US 3500 Onwards        Pages: 117
    This report studies the global Herpes Zoste Drug market status and forecast, categorizes the global Herpes Zoste Drug market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, India, Southeast Asia and other regions (Central & South America, and Middle East & Africa). The global Herpes Zoste Drug market is valued at million US$ in 2017 and will reach million US$ by the end of 2......
  • Global Crigler-Najjar Syndrome Drug Market Professional Survey Report 2018
    Published: 19-Jul-2018        Price: US 3500 Onwards        Pages: 109
    This report studies the global Crigler-Najjar Syndrome Drug market status and forecast, categorizes the global Crigler-Najjar Syndrome Drug market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, India, Southeast Asia and other regions (Central & South America, and Middle East & Africa). The global Crigler-Najjar Syndrome Drug market is valued at million US$ in 2017 and will ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs